Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
Provided herein are conjugates including a polypeptide and one or more drug molecules. The polypeptide includes one or more charged motifs, and may further include one or more uncharged motifs. The conjugates may be used to effectively deliver the drug molecule to a subject.
1. A conjugate comprising:
(a) a polypeptide comprising SEQ ID NO: 2 (VPX 1 X 2 G) n , wherein X 1 is a negatively or positively charged amino acid, X 2 is the other of a negatively or positively charged amino acid, and n is an integer from about 50 to about 500, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid, and the positively charged amino acid is independently selected from lysine and arginine, and wherein SEQ ID NO: 2 repeats in series about 50 to about 500 times; and
(b) one or more drug molecules attached to the polypeptide, wherein the one or more drug molecules are selected from a cancer therapeutic, nucleotide, polynucleotide, peptide, protein, carbohydrate, antibody, and a combination thereof.
2. The conjugate of claim 1 , wherein the polypeptide further comprises one or more uncharged motifs, each uncharged motif independently having an amino acid sequence consisting of SEQ ID NO: 3 (VPGXG), wherein X is any amino acid except proline.
3. The conjugate of claim 2 , wherein the polypeptide comprises a plurality of uncharged motifs.
4. The conjugate of claim 3 , wherein the plurality of uncharged motifs is repeated in tandem.
5. The conjugate of claim 2 , wherein one or more uncharged motifs are positioned between at least two adjacent charged motifs of the polypeptide.
6. The conjugate of claim 2 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 5 (VPX 1 X 2 G) n (VPGXG) m , wherein:
X 1 is a negatively or positively charged amino acid, X 2 is the other of a negatively or positively charged amino acid, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid, and the positively charged amino acid is independently selected from lysine and arginine;
X is any amino acid except proline;
n is an integer from about 50 to about 500; and
m is an integer greater than or equal to 1.
7. The conjugate of claim 2 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 6 (VPGXG) m (VPX 1 X 2 G) n , wherein:
X 1 is a negatively or positively charged amino acid, X 2 is the other of a negatively or positively charged amino acid, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid, and the positively charged amino acid is independently selected from lysine and arginine;
X is any amino acid except proline;
n is an integer from about 50 to about 500; and
m is an integer greater than or equal to 1.
8. The conjugate of claim 2 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 7 {(VPX 1 X 2 G)(VPGXG)} b , wherein:
X 1 is a negatively or positively charged amino acid, X 2 is the other of a negatively or positively charged amino acid, wherein the negatively charged amino acid is independently selected from glutamic acid and aspartic acid, and the positively charged amino acid is independently selected from lysine and arginine;
X is any amino acid except proline; and
b is an integer greater than or equal to 1.
9. The conjugate of claim 1 , wherein the polypeptide further comprises a linker, and wherein the one or more drug molecules are attached to the polypeptide via the linker.
10. The conjugate of claim 9 , wherein the linker comprises one or more cysteines.
11. The conjugate of claim 9 , wherein the linker comprises an amino acid sequence selected from SEQ ID NO: 8 (GGC), SEQ ID NO: 9 ((GGC) 8 ), SEQ ID NO: 10 ((G 4 S) 3 ), and SEQ ID NO: 11 ((VPGXG) 16 ) wherein X is valine or cysteine present in a ratio of 1:1.
12. The conjugate of claim 9 , wherein the drug molecule is attached to the polypeptide through a thiol reactive group in the linker.
13. The conjugate of claim 1 , wherein the drug molecule is a cancer therapeutic.
14. The conjugate of claim 1 , wherein the drug molecule is paclitaxel.
15. A method of treating a subject having a disease or disorder, the method comprising administering the conjugate of claim 1 to the subject, wherein the disease or disorder is a cancer, a metabolic disease, an autoimmune disease, a cardiovascular disease, or an orthopedic disorder.
16. The method of claim 15 , wherein the disease or disorder is cancer selected from breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer.
17. The conjugate of claim 2 , wherein the polypeptide further comprises a linker, and wherein the one or more drug molecules are attached to the polypeptide via the linker.
18. The conjugate of claim 17 , wherein the linker comprises one or more cysteines.
19. The conjugate of claim 17 , wherein the linker comprises an amino acid sequence selected from SEQ ID NO: 8 (GGC), SEQ ID NO: 9 ((GGC) 8 ), SEQ ID NO: 10 ((G 4 S) 3 ), and SEQ ID NO: 11 ((VPGXG) 16 ) wherein X is valine or cysteine present in a ratio of 1:1.
20. The conjugate of claim 17 , wherein the drug molecule is attached to the polypeptide through a thiol reactive group in the linker.
21. The conjugate of claim 1 , wherein the drug molecule is a protein.
22. The conjugate of claim 1 , wherein the drug molecule is an antibody.
23. The conjugate of claim 1 , wherein the drug molecule is Tn 3 TRAIL superagonist.